Low-Dose vs. Standard-Dose Nintedanib at Initiation in Fibrosing ILD: A Target-Trial Emulation of Treatment Persistence and Lung Function
In this target-trial emulation, starting at 100 mg twice daily improved 12-month treatment persistence. One-year FVC %predicted estimates among survivors were broadly similar but imprecise and should be interpreted with caution; a start-low, escalate-as-tolerated policy warrants prospective evaluation.
Authors
- Kazuo Kasahara (ORCID: https://orcid.org/0000-0001-5551-1543)
- Koichiro KAMIO
- Shota Kaburaki (ORCID: https://orcid.org/0000-0002-1194-087X)
- Namiko Taniuchi (ORCID: https://orcid.org/0000-0003-1897-5933)
- Toru Tanaka
- Masahiro Seike
- Yosuke Tanaka
Institutions
- Nippon Medical School (JP)
Publication Details
- Journal
- Annals of the American Thoracic Society
- Published
- 2026-03-22
- DOI
- https://doi.org/10.1093/annalsats/aaoag069
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00